Aptevo Therapeutics Inc. (APVO) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$1.58

From 52W high−94.51%

Volume8429.00

Market cap$2.90M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$1.58

From 52W high

−94.51%

Volume

8429.00

Market cap

$2.90M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.1x

P/E (TTM)

—

RSI (14)

29.5

MomentumView details →

1D Return

−1.23%

YTD Return

−83.03%

SummaryUpdated Jun 1, 2026

Aptevo Therapeutics Inc. (NASDAQ:APVO) is a clinical-stage biotechnology company founded in 2016 and headquartered in Seattle, Washington. The company emerged as a spinoff focused on developing innovative immunotherapeutic treatments for various forms of cancer. Aptevo specializes in creating bispecific antibodies, which are engineered proteins designed to simultaneously target two different antigens to enhance the body's immune response against cancer cells. The company has developed proprietary platform technologies called ADAPTIR and ADAPTIR-FLEX to create these specialized therapeutic candidates.

Ask drillr about Aptevo Therapeutics Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

0.1x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

0.5x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−437.15%

ROA (TTM)

−181.89%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+97.83%

FCF YoY

−2.82%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+99.72%

EBITDA YoY

−10.20%

MomentumView details →

1D Return

−1.23%

YTD Return

−83.03%

1Y Return

−94.51%

RSI (14)

29.5

vs 50D SMA

−26.39%

vs 200D SMA

−65.99%

Capital & dividendView details →

Debt/Equity

0.70x

Current Ratio

2.08x

Quick Ratio

2.08x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$5.31

EPS Surprise

11.79%

Beats (12Q)

7/12

Next Q EPS Est

−$3.14

Avg Surprise (4Q)

−3.41%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−26.41M

Op. CF (TTM)

−25.34M

Next earningsNov 5, 2026 →

Latest newsMore news →

Aptevo Therapeutics announced clinical trial results for its lead candidate mipletamig, reporting a 93% clinical benefit rate in frontline acute myeloid leukemia patients with TP53 mutations.47d ago

Similar companies

BioAtla, Inc.BCAB 60 Degrees Pharmaceuticals, Inc.SXTP Affimed N.V.AFMD Mustang Bio, Inc.MBIO Medicus Pharma Ltd.MDCXW Decoy Therapeutics Inc.DCOY Find similar companies →

Latest newsMore news →

Aptevo Therapeutics announced progress in its next-generation trispecific immuno-oncology programs, optimizing several trispecific candidates for scalable manufacturing ahead of future human testing.26d ago Aptevo Therapeutics announced clinical trial results for its lead candidate mipletamig, reporting a 93% clinical benefit rate in frontline acute myeloid leukemia patients with TP53 mutations.47d ago Aptevo Therapeutics entered into a 50/50 collaboration with Niowave to develop radiopharmaceutical therapeutics.67d ago